Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 4Neoplasms by Site 3Colorectal Neoplasms 3Neoplasms, Glandular and Epithelial 2Neoplasms by Histologic Type 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Non-Small-Cell Lung 2Thymus Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Pancreatic Neoplasms 1Pancreatic Diseases 1Mesothelioma, Malignant 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Colonic Diseases 1Carcinoma, Pancreatic Ductal 1Carcinoma, Hepatocellular 1Bronchial Neoplasms 1Advanced Gastrointestinal Cancer 1

Interventions

selpercatinib 2sotorasib 1pralsetinib 1patritumab 1osimertinib 1napabucasin 1icotinib 1durvalumab 1cobimetinib 1atezolizumab 1alectinib 1Radiosurgery 1Pemetrexed 1Paclitaxel 1Erlotinib Hydrochloride 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bronchial Neoplasms × napabucasin × Clear all
NCT02826161 2023-11-15

CanStem43L

Sumitomo Pharma America, Inc.

Phase 3 Terminated
4 enrolled 6 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡